LateTIME

Title: LateTIME – A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction.

Study Sponsor: NIH Grant awarded to The Cardiovascular Cell Therapy Research Network

Principal Investigator: Jay H. Traverse, MD

Study Status: CLOSED TO ENROLLMENT

Study Synopsis: This study is testing the safety and effectiveness of giving a person’s own stem cells 2 to 3 weeks after a heart attack. Stem cells are simple cells that can help your injured tissues repair themselves and may help grow new blood vessels. The stem cells may help your body repair the damage that occurs with a large heart attack. It is possible that these cells will decrease the size of damage caused to your heart from your heart attack and increase the pumping efficiency of your heart that may be depressed after a heart attack. This repair function may help your heart repair itself and improve the pumping function. 87 patients will be enrolled at 5 centers around the country. Up to 50 patients may be enrolled at Abbott Northwestern Hospital. Your follow up in the study lasts 2 years at the Minneapolis Heart Institute at Abbott Northwestern. Five visits are required. The follow up visits can be completed in one day.

How do I qualify? Patients who have had their first heart attack that affected the front wall of their heart (often referred to as the “widow-maker”) and have depressed pumping function can be considered for participation. Consideration for participation in this study begins on the day of your heart attack. You must be willing and able to receive treatment between 14 and 21 days after your heart attack. Other factors are also checked to see if it is safe for you to participate in the study.

Whom do I contact for more information? Rachel Olson, RN, MS, CCRC or contact research at 612.863.3980.